Colorectal Cancer Diagnostic and Treatment Market - Forecasts from 2018 to 2023

March 2018 | 89 pages | ID: C7D9DC88A9FEN
Knowledge Sourcing Intelligence LLP

Abstracts

The global colorectal cancer diagnostic and treatment market was valued at US$13.927 billion in 2017 and is projected to expand at a CAGR of 4.22% over the forecast period to reach US$17.842 billion by 2023. Colorectal cancer is the cancer starting either in the colon or rectum. These can also be named as either colon cancer or rectal cancer depending on where they start. Cancer starts when there is an abnormal cell proliferation and these spread to the other parts of the body as well. The primary cause of the disease is due to the adoption of unhealthy lifestyle conditions such as consumption of processed meat and alcoholic drinks. Rise in aging population, increased healthcare spending, growing disease prevalence and increasing awareness in emerging economies are the driving factors. United States in North America has the maximum disease prevalence and hold a significant market share in the global colorectal cancer diagnostic and treatment market.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the colorectal cancer diagnostic and treatment value chain. Last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global colorectal cancer diagnostic and treatment market.

Major industry players profiled as part of the report are Celgene Corporation, Eli Lilly and Company, Amgen Limited, and AstraZeneca among others.

SEGMENTATION

The global Colorectal Cancer Diagnostic and Treatment market has been analyzed through following segments:

• By Diagnostics
• Colonoscopy
• Biopsy
• Blood Tests
• Others
• By Therapeutics
• Laparoscopic Surgery
• Radiation Therapy
• Radiofrequency Ablation (RFA) or Cryoablation
• Others
• By Geography
• Americas
• United States
• Canada
• Brazil
• Others
• Europe Middle East and Africa
• United Kingdom
• Germany
• France
• Netherlands
• Others
• Asia Pacific
• China
• Japan
• India
• Australia
• Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL COLORECTAL CANCER DIAGNOSTIC AND TREATMENT MARKET BY DIAGNOSTICS

5.1. Colonoscopy
5.2. Biopsy
5.3. Blood Tests
5.4. Others

6. GLOBAL COLORECTAL CANCER DIAGNOSTIC AND TREATMENT MARKET BY THERAPEUTICS

6.1. Laparoscopic Surgery
6.2. Radiation Therapy
6.3. Radiofrequency Ablation (RFA) or Cryoablation
6.4. Others

7. GLOBAL COLORECTAL CANCER DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

7.1. Americas
  7.1.1. United States
  7.1.2. Canada
  7.1.3. Brazil
  7.1.4. Others
7.2. Europe Middle East and Africa
  7.2.1. United Kingdom
  7.2.2. Germany
  7.2.3. France
  7.2.4. Netherlands
  7.2.5. Others
7.3. Asia Pacific
  7.3.1. China
  7.3.2. Japan
  7.3.3. India
  7.3.4. Australia
  7.3.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Recent Deals and Investment
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Celgene Corporation
  9.1.1. Company Overview
  9.1.2. Financials
  9.1.3. Products and Services
  9.1.4. Recent Developments
9.2. Bristol-Myers Squibb Company
  9.2.1. Company Overview
  9.2.2. Financials
  9.2.3. Products and Services
  9.2.4. Recent Developments
9.3. Eli Lilly and Company
  9.3.1. Company Overview
  9.3.2. Financials
  9.3.3. Products and Services
  9.3.4. Recent Developments
9.4. Amgen Limited
  9.4.1. Company Overview
  9.4.2. Financials
  9.4.3. Products and Services
  9.4.4. Recent Developments
9.5. AstraZeneca
  9.5.1. Company Overview
  9.5.2. Financials
  9.5.3. Products and Services
  9.5.4. Recent Developments
9.6. Biocon
  9.6.1. Company Overview
  9.6.2. Financials
  9.6.3. Products and Services
  9.6.4. Recent Developments
9.7. F.Hoffmann-La Roche Ltd.
  9.7.1. Company Overview
  9.7.2. Financials
  9.7.3. Products and Services
  9.7.4. Recent Developments